Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations Conference PaperKirk SmithJuly 1, 2021Lorlatinib, Treatment-Naïve Patients, ALK +, Non-Small Cell Lung Cancer (NSCLC), EML4-ALK Variants, https://cancerres.aacrjournals.org/content/81/13_Supplement/LB043.short
